قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ The official FDA warnings against buying young blood

The official FDA warnings against buying young blood



The US Food and Drug Administration is an official warning to consumers that buying young blood infusions to improve their health is not a good idea. It is, in fact, a very bad idea because there is no clinical evidence that these infusions do anything, and the procedure can be dangerous.

"In other words, we are concerned that some patients become infected by innocent actors who heal plasma treatment from young donors as healing and remedies," wrote the FDA Commissioner Scott Gottlieb and Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Warning. "Such treatments have no proven clinical benefits for the use of which clinics are advertising them and potentially harmful."

The idea that young blood infusions may slow the aging has since the early 2000s, when mouse studies show good results. (Interestingly, young and old mice do not just share blood, they are attached and actually share organs.) The concept really got traction a few years ago, thanks for part in a rumor that venture capitalist Peter Thiel is interested in the transfusion. As other sites, including Bloomberg have stated, despite the ridiculous nature of the claim, jokes about vampirism, and the spoof of the show Silicon Valley blood clinics exist. Interestingly, a startup called Ambrosia Medical has promised transfers for $ 8,000 a liter. "It works," Ambrosia founder Jesse Karmazin told reporters Mic . "It reverses aging."

There is hardly any evidence that this claim is true. Some researchers made the original blood-blood test showed (again in mice) that the old blood was painful more than the blood-assisted children and suggested that it would be a better idea to Instead, study only why old blood is harmful. In 201

7, a rigorous clinical trial found that young blood given to 18 Alzheimer's patients was virtually absent to treat the disease. Not only is it ineffective, but typical translations can be dangerous, leading to a few dozen deaths reported to the FDA each year.

Clearly more research on this "treatment" is required, although companies have not stopped such as Ambrosia from selling them to humans. A Huffington Post found an investigation that Karmazin was not permitted to practice medicine in Massachusetts, ran a less-educated study of the effectiveness of blood-free blood groups , and did not release any information from the study, despite the continued retribution of people.

Repeatedly, scientists have identified no good data to support this practice. Finally the FDA agrees. So please, if the lack of clinical evidence and remarkable startup skills does not stop enough, listen to the FDA on this one.


Source link